Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Andre C. Kalil,Thomas F. Patterson,Aneesh K. Mehta,Kay M. Tomashek,Cameron R. Wolfe,Varduhi Ghazaryan,Vincent C. Marconi,Guillermo M. Ruiz-Palacios,Lanny Hsieh,Susan Kline,Victor F. Tapson,Nicole M. Iovine,Mamta K. Jain,Daniel A. Sweeney,Hana M. El Sahly,Angela Branche,Justino Regalado Pineda,David C. Lye,Uriel Sandkovsky,Anne F Luetkemeyer,Stuart H. Cohen,Robert W. Finberg,Patrick E. H. Jackson,Babafemi Taiwo,Catharine I. Paules,Henry Arguinchona,Nathaniel B. Erdmann,Neera Ahuja,Maria G. Frank,Myoung Don Oh,Eu-Suk Kim,Seow Y Tan,Richard A. Mularski,Henrik Nielsen,Philip O Ponce,Barbara S. Taylor,LuAnn Larson,Nadine Rouphael,Youssef Saklawi,Valeria D Cantos,Emily R Ko,John J. Engemann,Alpesh Amin,Miki Watanabe,Joanne Billings,Marie-Carmelle Elie,Richard T. Davey,Timothy Burgess,Jennifer Ferreira,Michelle Green,Mat Makowski,Anabela Cardoso,Stephanie de Bono,Tyler Bonnett,Michael A. Proschan,Gregory A. Deye,Walla Dempsey,Seema U Nayak,Lori E. Dodd,John H. Beigel +59 more
TLDR
Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.Abstract:
Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. Methods We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. Results A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P = 0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P = 0.003). Conclusions Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.).read more
Citations
More filters
Journal ArticleDOI
SARS-CoV-2 Infection and COVID-19 in Children
Alpana Waghmare,Diego R. Hijano +1 more
TL;DR: In this article , the authors provide an overview of the clinical manifestations of coronavirus disease 2019 in children, including the post-infectious phenomenon called multisystem inflammatory syndrome in children.
Journal ArticleDOI
Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand
Thummaporn Naorungroj,Tanuwong Viarasilpa,Surat Tongyoo,Aeckapholpholladet Detkaew,Thanchanok Pinpak,Rawish Wimolwattanaphan,Ranistha Ratanarat,Panuwat Promsin,Preecha Thamrongpiroj,Akekarin Phumpichet,Chairat Permpikul +10 more
TL;DR: In this article , the authors reviewed the medical records of patients who had COVID-19 infection and were admitted to the cohort ward or ICUs at Siriraj Hospital between January 2020 and December 2021.
Journal ArticleDOI
Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19—A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan
Shinobu Tamura,Takahiro Kaki,Mayako Niwa,Yukiko Yamano,Shintaro Kawai,Yusuke Yamashita,Harumi Tanaka,Yoshinobu Saito,Yoshinori Kajimoto,Yusuke Koizumi,Hiroki Yamaue,Naoyuki Nakao,Takako Nojiri,Masaya Hironishi +13 more
TL;DR: Many patients with mild to moderate COVID-19 required the therapeutic intervention of remdesivir during the fourth pandemic period in Wakayama, Japan, and from the clinical data obtained at admission, these risk factors could contribute to a prediction regarding the requirement of remDesivir treatment.
Posted ContentDOI
Combination of Baricitinib plus Remdesivir and Dexamethasone improves time to recovery and mortality among hospitalized patients with severe COVID-19 infection
V. Perez Gutierrez,Vishwa Shah,A.M. Afzal,Annam Khalid,Ariane Yangco,S. Ocrospoma,Nail Cemalovic,Ashwati S Pillai,Moiz Kasubhai,Vihren Dimitrov,V. S. Menon +10 more
TL;DR: Baricitinib with standard therapy reduced time to recovery and offer mortality benefit in patients with severe COVID-19 pneumonia.
Posted ContentDOI
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Richard A. Miller,Pramod Guru,Philippe R. Bauer,Jorge Robles,Christian Tomaszewski,J. Scott Overcash,Michael F. Waters,Miriam L Cameron,Julián Olalla Sierra,Haider Mashhedi,Mehrdad Mobasher,James W. Janc,Jenny A. Rudnick,Shenshen Hu,William B. Jones,Long Kwei,Suresh Mahabhashyam,Stephen Willingham,Gerard J. Criner +18 more
TL;DR: In this paper, a humanized anti-CD73 antibody, mupadolimab (CPI-006), was developed to block CD73 enzymatic activity and activate CD73POS B cells, thereby inducing differentiation into plasmablasts and antibody secretion independent of the adenosine modulatory activity.
References
More filters
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
TL;DR: The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Journal ArticleDOI
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Journal ArticleDOI
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Peter D. Richardson,Ivan Griffin,Catherine Tucker,Daniel J. Smith,Olly Oechsle,Anne Phelan,Michael J. Rawling,Edward Savory,Justin Stebbing +8 more
TL;DR: It is suggested that baricitinib could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.
Journal ArticleDOI
COVID-19: combining antiviral and anti-inflammatory treatments
Justin Stebbing,Anne Phelan,Ivan Griffin,Catherine Tucker,Olly Oechsle,Daniel J. Smith,Peter D. Richardson +6 more
TL;DR: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, and convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
Related Papers (5)
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Hongchao Pan,Richard Peto,Ana-Maria Henao-Restrepo,Marie-Pierre Preziosi,Vasee Sathiyamoorthy,Quarraisha Abdool Karim,Marissa M. Alejandria,César Hernández García,Marie-Paule Kieny,Reza Malekzadeh,Srinivas Murthy,K. Srinath Reddy,Mirta Roses Periago,Pierre Abi Hanna,Florence Ader,Abdullah M. Al-Bader,Almonther Alhasawi,Emma Allum,Athari Alotaibi,Carlos A Alvarez-Moreno,Sheila Appadoo,Abdullah Asiri,Pål Aukrust,Andreas Barratt-Due,Samir Bellani,Mattia Branca,Heike B. C. Cappel-Porter,Nery Cerrato,Ting S. Chow,Najada Como,Joseph A. Eustace,Patricia J. Garcia,Sheela Godbole,Eduardo Gotuzzo,Laimonas Griskevicius,Rasha Hamra,Mariam Hassan,Mohamed Hassany,David Hutton,Irmansyah Irmansyah,Ligita Jancoriene,Jana Kirwan,Suresh Kumar,Peter Lennon,Gustavo Lopardo,Patrick Lydon,Nicola Magrini,Teresa Maguire,Suzana Manevska,Oriol Manuel,Sibylle McGinty,Marco T. Medina,María L. Mesa Rubio,Maria C. Miranda-Montoya,Jeremy Nel,Estevão Portela Nunes,Markus Perola,Antonio Portolés,Menaldi R. Rasmin,Aun Raza,Helen Rees,Paula P. S. Reges,Chris A Rogers,Kolawole Salami,Marina I. Salvadori,Narvina Sinani,Jonathan A C Sterne,Milena Stevanovikj,Evelina Tacconelli,Kari A.O. Tikkinen,Sven Trelle,Hala Zaid,John-Arne Røttingen,Soumya Swaminathan +73 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more